Prescription Drugs - Suriname

  • Suriname
  • In Suriname, the revenue in the Prescription Drugs market is estimated to reach US$25.08m in 2024.
  • Furthermore, it is expected that the revenue will display an annual growth rate (CAGR 2024-2029) of 1.24%, which will result in a market volume of US$26.67m by 2029.
  • When compared globally, it is noteworthy that United States will generate the highest revenue, reaching US$358.90bn in 2024.
  • Additionally, in terms of per person revenues, in Suriname will generate US$39.88 in 2024.
  • Suriname's prescription drug market is experiencing a surge in demand for affordable generic medications.

Key regions: Japan, China, Europe, Australia, Canada

 
Market
 
Region
 
Region comparison
 
Currency
 

Analyst Opinion

The Prescription Drugs (Pharmacies) market in Suriname is experiencing significant growth and development due to various factors. Customer preferences in Suriname play a crucial role in shaping the Prescription Drugs (Pharmacies) market. Customers in Suriname have a growing demand for a wide range of prescription drugs, including both generic and branded medications. This preference is driven by the need for affordable healthcare options and the availability of a diverse range of medications to treat various health conditions. Additionally, customers in Suriname value convenience and accessibility when it comes to purchasing prescription drugs, which has led to the proliferation of pharmacies across the country. Trends in the Prescription Drugs (Pharmacies) market in Suriname reflect global and regional developments. One prominent trend is the increasing adoption of e-commerce platforms by pharmacies in Suriname. This trend is driven by the growing use of technology and the internet, which has made it easier for customers to purchase prescription drugs online. E-commerce platforms offer convenience, competitive pricing, and a wide selection of medications, making them an attractive option for customers in Suriname. Another trend in the market is the emphasis on quality and safety of prescription drugs. Customers in Suriname are becoming more aware of the importance of purchasing medications from reputable sources. This has led to an increased focus on regulatory compliance and quality control measures by pharmacies in Suriname. Pharmacies are investing in systems and processes to ensure that the prescription drugs they sell meet the necessary standards and regulations. Local special circumstances in Suriname also contribute to the development of the Prescription Drugs (Pharmacies) market. Suriname has a relatively small population, which presents both opportunities and challenges for pharmacies. On one hand, the small population allows pharmacies to have a more personalized approach to customer service and build strong relationships with their customers. On the other hand, the small population size limits the potential customer base and may result in intense competition among pharmacies. Underlying macroeconomic factors also influence the Prescription Drugs (Pharmacies) market in Suriname. Economic growth and increasing disposable incomes have contributed to the growing demand for prescription drugs. As the economy continues to develop, more individuals in Suriname are able to afford healthcare services and medications, driving the growth of the market. Additionally, government initiatives and policies to improve healthcare access and affordability have further stimulated the Prescription Drugs (Pharmacies) market in Suriname. In conclusion, the Prescription Drugs (Pharmacies) market in Suriname is experiencing growth and development driven by customer preferences, global and regional trends, local special circumstances, and underlying macroeconomic factors. The increasing demand for a wide range of prescription drugs, the adoption of e-commerce platforms, and the emphasis on quality and safety are shaping the market in Suriname. Additionally, the small population size and economic growth in the country contribute to the market's development.

Methodology

Data coverage:

The data encompasses B2C enterprises. Figures are based on offline and online spending by consumers, including VAT. Not included are B2B and B2G sales, or other pharmaceutical sales through hospitals or retail stores such as supermarkets.

Modeling approach:

Market sizes are determined through a bottom-up approach, building on specific predefined factors for each market market. As a basis for evaluating markets, we use industry associations, third-party studies and reports and survey results from our primary research (e.g., the Statista Global Consumer Survey). In addition, we use relevant key market indicators and data from country-specific associations, such as healthcare expenditure per country, consumer healthcare spending, GDP and internet penetration. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the relevant market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. For forecasting digital trends such as the online-pharmacy sales share we use exponential trend smoothing and the s-curve method. The main drivers are healthcare expenditure per country and consumer healthcare spending.

Additional notes:

The data is modeled using current exchange rates. The impact of the COVID-19 pandemic and the Russia-Ukraine war are considered at a country-specific level. The market is updated twice a year. GCS data is reweighted for representativeness.

Overview

  • Revenue
  • Analyst Opinion
  • Global Comparison
  • Methodology
  • Key Market Indicators
Please wait

Contact

Get in touch with us. We are happy to help.
Statista Locations
Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (United States)

Mon - Fri, 9am - 6pm (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asia)

Mon - Fri, 9am - 5pm (SGT)

Contact Kisara Mizuno
Kisara Mizuno
Senior Business Development Manager– Contact (Asia)

Mon - Fri, 10:00am - 6:00pm (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Mon - Fri, 9:30am - 5pm (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Latin America)

Mon - Fri, 9am - 6pm (EST)